For the year ending 2025-12-31, ERNAW has $5,834K in assets. $3,433K in debts.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash | 1,884 | |||
| Other receivables | 95 | |||
| Due from related party | 750 | |||
| Prepaid expenses and other current assets | 404 | |||
| Total current assets | 3,133 | |||
| Property and equipment, gross | 291 | |||
| Less accumulated depreciation and amortization | 197 | |||
| Property and equipment, net | 94 | |||
| Right-of-use assets - operating leases, net | 453 | |||
| Goodwill | 2,044 | |||
| Other assets | 110 | |||
| Total assets | 5,834 | |||
| Accounts payable | 1,125 | |||
| Accrued expenses | 898 | |||
| Income taxes payable | 3 | |||
| Due to related party | 750 | |||
| Operating lease liabilities, current | 213 | |||
| Contingent consideration liability, current | 41 | |||
| Other current liabilities | 83 | |||
| Total current liabilities | 3,113 | |||
| Operating lease liabilities, non-current | 277 | |||
| Other liabilities | 43 | |||
| Total liabilities | 3,433 | |||
| Preferred stock, 0.005 par value, 1,000 shares authorized, 156 designated and outstanding of series a convertible preferred stock at december 31, 2025 and 2024, 156 liquidation preference | 1 | |||
| Common stock, 0.005 par value, 150,000 and 100,000 shares authorized at december 31, 2025 and2024, respectively, 7,854 and 3,426 issued and outstanding at december 31, 2025 and 2024, respectively | 39 | |||
| Additional paid-in capital | 247,997 | |||
| Accumulated deficit | -245,636 | |||
| Total stockholders equity | 2,401 | |||
| Total liabilities and stockholders equity | 5,834 | |||
Ernexa Therapeutics Inc. (ERNAW)
Ernexa Therapeutics Inc. (ERNAW)